PRE
Title: Coronavirus disease 2019
ID: 984186746
FULLTEXT: <td class="diff-addedline"><div>There are no proven [[COVID-19 vaccine|vaccines]] or [[COVID-19 drug development|specific treatments]] for COVID-19 yet, though several are in development. Management involves the [[Palliative care|treatment of symptoms]], [[Symptomatic treatment|supportive care]], [[isolation (health care)|isolation]], and [[Medical research|experimental measures]]. The [[World Health Organization]] (WHO) declared the COVID-19 [[Disease outbreak|outbreak]] a [[Public Health Emergency of International Concern]] (PHEIC)&lt;ref&gt;{{cite web|url=https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)|title=Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)|website=[[World Health Organization]] (WHO)|access-date=11 February 2020|archive-url=https://web.archive.org/web/20200131005904/https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)|archive-date=31 January 2020|url-status=live |name-list-format=vanc}}&lt;/ref&gt;&lt;ref&gt;{{cite news |vauthors=Mahtani S, Berger M, O'Grady S, Iati M |url=https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/02/05/114ced8a-479c-11ea-bc78-8a18f7afcee7_story.html |title=Hundreds of evacuees to be held on bases in California; Hong Kong and Taiwan restrict travel from mainland China |work=[[The Washington Post]] |date=6 February 2020 |access-date=11 February 2020 |archive-url=https://web.archive.org/web/20200207134650/https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/02/05/114ced8a-479c-11ea-bc78-8a18f7afcee7_story.html |archive-date=7 February 2020 |url-status=live |name-list-format=vanc}}&lt;/ref&gt; on 30 January 2020 and a [[COVID-19 pandemic|pandemic]] on 11 March 2020.&lt;ref name="WHOPandemic"&gt;{{cite press release|title=WHO Director-General's opening remarks at the media briefing on COVID-19|website=[[World Health Organization]] (WHO)|date=11 March 2020|url=https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020|access-date=12 March 2020|url-status=live|archive-url=https://web.archive.org/web/20200311212521/https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020|archive-date=11 March 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984186746
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984186746&oldid=984182414


PRE
Title: Coronavirus disease 2019
ID: 984215692
FULLTEXT: <td class="diff-addedline"><div>&lt;!-- DO NOT INTERFERE WITH THE SECTION BEGIN/END TAGS, AS IT WILL BREAK THE PANDEMIC ARTICLE --&gt;&lt;section begin="Spread" /&gt;[[Transmission of COVID-19|COVID-19 spreads]] most often when people are physically close.{{efn|Known as "close contact" which is variously defined, including within ~1.8 metres (six feet) by the US [[Centers for Disease Control and Prevention]] (CDC), and being face to face for at least 15 minutes, or sharing an enclosed space for a prolonged period such as 2 hours, by the Australian Health Department.&lt;ref&gt;{{cite web |title=Quarantine for coronavirus (COVID-19) |url=https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/how-to-protect-yourself-and-others-from-coronavirus-covid-19/quarantine-for-coronavirus-covid-19#what-is-a-close-contact |website=Australian Government Department of Health |accessdate=25 September 2020}}&lt;/ref&gt;&lt;ref name="CDCTrans"&gt;{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html |title=How COVID-19 Spreads |date=18 September 2020 |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |url-status=live |archive-url=https://web.archive.org/web/20200919224920/https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Ftransmission.html |archive-date=19 September 2020 |access-date=20 September 2020}}&lt;/ref&gt;|name=|group=}} It spreads very easily and sustainably through the air, primarily via [[Respiratory droplet|small droplets]] <ins class="diffchange diffchange-inline">or</ins> [[Airborne transmission|aerosols]], as an infected person breathes, coughs, sneezes, talks, or sings.&lt;ref name="CDCTrans" /&gt;&lt;ref name="ECDCTRANSMIT"&gt;{{Cite web|title=Transmission of COVID-19|url=https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission|access-date=12 September 2020|website=European Centre for Disease Prevention and Control|language=en}}&lt;/ref&gt; It may also be transmitted via [[fomite|contaminated surfaces]], although this has not been conclusively demonstrated.&lt;ref name="ECDCTRANSMIT" /&gt;&lt;ref name="WHOTRANS"&gt;{{Cite web|title=Q&amp;A: How is COVID-19 transmitted?|url=https://www.who.int/news-room/q-a-detail/q-a-how-is-covid-19-transmitted|access-date=12 July 2020|website=[[World Health Organization]] (WHO)}}&lt;/ref&gt;&lt;ref name="WHOTransBrief"&gt;{{cite web |url=https://apps.who.int/iris/rest/bitstreams/1286634/retrieve |website=[[World Health Organization|www.who.int]] |title=Transmission of SARS-CoV-2: implications for infection prevention precautions |publisher=World Health Organization |accessdate=18 September 2020 |format=PDF |date=9 July 2020 |archive-url=https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions |archive-date=9 July 2020 |url-status=live<ins class="diffchange diffchange-inline">}}&lt;/ref&gt; Airborne transmission from aerosol formation is suspected to be the main mode of transmission.&lt;ref&gt;{{cite journal |last1=Karia |first1=R. |last2=Gupta |first2=I. |last3=Khandait |first3=H. |title=COVID-19 and its Modes of Transmission |journal=SN Compr Clin Med. |date=2020 |issue=2 |pages=1798–1801 |doi=10.1007/s42399-020-00498-4 |pmid=32904860 |url=https://link.springer.com/article/10.1007%2Fs42399-020-00498-4 |accessdate=18 October 2020</ins>}}&lt;/ref&gt; It can spread from an infected person for up to two days prior to symptom onset and from people who are [[asymptomatic]].&lt;ref name="ECDCTRANSMIT" /&gt; People remain infectious for seven to twelve days in moderate cases and up to two weeks in severe cases.&lt;ref name="ECDCTRANSMIT" /&gt;&lt;ref name="ECDCQA" /&gt;&lt;!-- DO NOT REMOVE THE FOLLOWING TAG --&gt;&lt;section end="Spread" /&gt; The standard method of [[diagnosis]] is by [[Reverse transcription polymerase chain reaction|real-time reverse transcription polymerase chain reaction]] (rRT-PCR) from a [[nasopharyngeal swab]].</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984215692
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984215692&oldid=984214629


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Outside the human body, the virus is destroyed by household soap, which bursts its [[Viral envelope|protective bubble]].&lt;ref name="NatGeoSoap"&gt;{{Cite web |url=https://www.nationalgeographic.com/science/2020/03/why-soap-preferable-bleach-fight-against-coronavirus/ |title=Why soap is preferable to bleach in the fight against coronavirus |date=18 March 2020 |website=[[National Geographic]] |url-status=live |archive-url=https://web.archive.org/web/20200402001042/https://www.nationalgeographic.com/science/2020/03/why-soap-preferable-bleach-fight-against-coronavirus/ |archive-date=2 April 2020 |access-date=2 April 2020 |vauthors=Gibbens S }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>The virus can cause [[Myocardial infarction|acute myocardial injury]] and chronic damage to the [[Circulatory system|cardiovascular system]].&lt;ref name=":3"&gt;{{cite journal |vauthors=Zheng YY, Ma YT, Zhang JY, Xie X |title=COVID-19 and the cardiovascular system |journal=Nature Reviews. Cardiology |volume=17 |issue=5 |pages=259–260 |date=May 2020 |pmid=32139904 |pmc=7095524 |doi=10.1038/s41569-020-0360-5}}&lt;/ref&gt; An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,&lt;ref name="Huang24Jan2020" /&gt; and is more frequent in severe disease.&lt;ref&gt;{{cite web | title=Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues | website=UpToDate | url=https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-myocardial-infarction-and-other-coronary-artery-disease-issues | access-date=28 September 2020}}&lt;/ref&gt; Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.&lt;ref name=":3" /&gt; ACE2 receptors are highly expressed in the heart and are involved in heart function.&lt;ref name=":3" /&gt;&lt;ref&gt;{{cite journal |vauthors=Turner AJ, Hiscox JA, Hooper NM |title=ACE2: from vasopeptidase to SARS virus receptor |journal=Trends in Pharmacological Sciences |volume=25 |issue=6 |pages=291–4 |date=June 2004 |pmid=15165741 |pmc=7119032 |doi=10.1016/j.tips.2004.04.001 |doi-access=free}}&lt;/ref&gt; A high incidence of [[thrombosis]] and [[venous thromboembolism]] have been found in ICU patients with COVID-19 infections, and may be related to poor prognosis.&lt;ref&gt;{{cite journal | last1=Abou-Ismail | first1=Mouhamed Yazan | last2=Diamond | first2=Akiva | last3=Kapoor | first3=Sargam | last4=Arafah | first4=Yasmin | last5=Nayak | first5=Lalitha | title=The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management | journal=Thrombosis Research | publisher=Elsevier BV | volume=194 | date=2 June 2020| issn=0049-3848 | pmid=32788101 | pmc=7305763 | doi=10.1016/j.thromres.2020.06.029 | pages=101–115}}&lt;/ref&gt; Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to [[pulmonary embolism]]s, and [[stroke|ischaemic events]] within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of [[vasoconstriction|vasoconstrictive responses]] within the body, constriction of blood vessels within the [[pulmonary circulation]] has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.&lt;ref name="Science"&gt;{{cite journal |last=Wadman |first=Meredith |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |doi=10.1126/science.abc3208 |title=How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes |journal=Science |date=April 2020 |doi-access=free}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[File:CDC 2019-nCoV Laboratory Test Kit.jpg|thumb|[[Centers for Disease Control and Prevention|US CDC]] [[rRT-PCR]] test kit for COVID-19&lt;ref&gt;{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html |title=CDC Tests for 2019-nCoV |date=5 February 2020 |website=U.S. [[Centers for Disease Control and Prevention]] |url-status=live |archive-url=https://web.archive.org/web/20200214023335/https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html |archive-date=14 February 2020 |access-date=12 February 2020 }}&lt;/ref&gt;]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>The WHO has published several testing protocols for the disease.&lt;ref&gt;{{cite web|url=https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117|title=Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases|website=[[World Health Organization]] (WHO)|access-date=13 March 2020|archive-url=https://web.archive.org/web/20200317023052/https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117|archive-date=17 March 2020|url-status=live}}&lt;/ref&gt; The standard method of testing is [[real-time reverse transcription polymerase chain reaction]] (rRT-PCR).&lt;ref name="20200130cdc"&gt;{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/summary.html |title=2019 Novel Coronavirus (2019-nCoV) Situation Summary |date=30 January 2020 |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |url-status=live |archive-url=https://web.archive.org/web/20200126210549/https://www.cdc.gov/coronavirus/2019-nCoV/summary.html |archive-date=26 January 2020 |access-date=30 January 2020 }}&lt;/ref&gt; The test is typically done on respiratory samples obtained by a [[nasopharyngeal swab]]; however, a nasal swab or sputum sample may also be used.&lt;ref name="CDC2020Testing"&gt;{{cite web|date=11 February 2020|title=Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)|url=https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html|url-status=live|archive-url=https://web.archive.org/web/20200304165907/https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html|archive-date=4 March 2020|access-date=26 March 2020|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)}}&lt;/ref&gt;&lt;ref name="20200129cdc"&gt;{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |title=Real-Time RT-PCR Panel for Detection 2019-nCoV |date=29 January 2020 |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200130202031/https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |archive-date=30 January 2020 |url-status=live }}&lt;/ref&gt; Results are generally available within a few hours to two days.&lt;ref name="globenewswire1977226"&gt;{{cite web |url=https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |title=Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe |date=30 January 2020 |website=GlobeNewswire News Room |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200131201626/https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |archive-date=31 January 2020 |url-status=live }}&lt;/ref&gt;&lt;ref name="20200130businessinsider"&gt;{{cite web |url=https://www.businessinsider.com/how-to-know-if-you-have-the-coronavirus-pcr-test-2020-1 |title=There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus |last=Brueck |first=Hilary |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=30 January 2020 |website=Business Insider |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200201034232/https://www.businessinsider.com/how-to-know-if-you-have-the-coronavirus-pcr-test-2020-1 |archive-date=1 February 2020 |url-status=live}}&lt;/ref&gt; Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value.&lt;ref&gt;{{cite web |url=https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 |title=Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases |access-date=26 February 2020 |archive-url=https://web.archive.org/web/20200221192745/https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 |archive-date=21 February 2020 |url-status=live}}&lt;/ref&gt; Chinese scientists were able to isolate a strain of the coronavirus and publish the [[Nucleic acid sequence|genetic sequence]] so laboratories across the world could independently develop [[polymerase chain reaction]] (PCR) tests to detect infection by the virus.&lt;ref name="Hui14Jan2020"&gt;{{cite journal | vauthors = Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E | display-authors = 6 | title = The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China | journal = International Journal of Infectious Diseases | volume = 91 | issue = | pages = 264–266 | date = February 2020 | pmid = 31953166 | pmc = 7128332 | doi = 10.1016/j.ijid.2020.01.009 | doi-access = free }}&lt;/ref&gt;&lt;ref name="Cohen17Jan20202"&gt;{{cite journal | vauthors = Cohen J, Normile D | title = New SARS-like virus in China triggers alarm | journal = Science | volume = 367 | issue = 6475 | pages = 234–235 | date = January 2020 | pmid = 31949058 | doi = 10.1126/science.367.6475.234 | url = https://mcb.uconn.edu/wp-content/uploads/sites/2341/2020/01/WuhanScience24Jan2020.pdf | access-date = 11 February 2020 | url-status = live | s2cid = 210701594 | bibcode = 2020Sci...367..234C | archive-url = https://web.archive.org/web/20200211230310/https://mcb.uconn.edu/wp-content/uploads/sites/2341/2020/01/WuhanScience24Jan2020.pdf | archive-date = 11 February 2020 }}&lt;/ref&gt;&lt;ref name="ncbiWuhanGenomes"&gt;{{cite web |url=https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=Wuhan%20seafood%20market%20pneumonia%20virus,%20taxid:2697049 |title=Severe acute respiratory syndrome coronavirus 2 data hub |website=NCBI |url-status=live |access-date=4 March 2020 |archive-url=https://web.archive.org/web/20200321235550/https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=Wuhan%20seafood%20market%20pneumonia%20virus,%20taxid:2697049 |archive-date=21 March 2020}}&lt;/ref&gt; {{As of|2020|April|4}}, [[antibody titer|antibody tests]] (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.&lt;ref&gt;{{cite journal | vauthors = Petherick A | title = Developing antibody tests for SARS-CoV-2 | journal = Lancet | volume = 395 | issue = 10230 | pages = 1101–1102 | date = April 2020 | pmid = 32247384 | pmc = 7270070 | doi = 10.1016/s0140-6736(20)30788-1 | doi-access = free }}&lt;/ref&gt;&lt;ref name="Vogel2020"&gt;{{cite journal |title=New blood tests for antibodies could show true scale of coronavirus pandemic |last=Vogel |first=Gretchen |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |journal=Science |doi=10.1126/science.abb8028|date=March 2020 |doi-access=free}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, Gutierrez RA, Gwee SX, Chua PE, Yang Q, Ng XY, Yap RK, Tan HY, Teo YY, Tan CC, Cook AR, Yap JC, Hsu LY | display-authors = 6 | title = Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review | journal = Journal of Clinical Medicine | volume = 9 | issue = 3 | pages = 623 | date = February 2020 | pmid = 32110875 | pmc = 7141113 | doi = 10.3390/jcm9030623 | doi-access = free }}&lt;/ref&gt; Antibody tests may be most accurate 2–3 weeks after a person's symptoms start.&lt;ref&gt;{{cite journal | vauthors = Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A | display-authors = 6 | title = Antibody tests for identification of current and past infection with SARS-CoV-2 | journal = The Cochrane Database of Systematic Reviews | volume = 6 | pages = CD013652 | date = June 2020 | pmid = 32584464 | pmc = 7387103 | doi = 10.1002/14651858.CD013652 | s2cid = 220061130 }}&lt;/ref&gt; The Chinese experience with testing has shown the [[Sensitivity and specificity|accuracy]] is only 60 to 70%.&lt;ref&gt;AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". [https://www.aljazeera.com/news/2020/04/false-negatives-complicating-covid-19-testing-200411100741669.html Al Jazeera website] Retrieved 12 April 2020.&lt;/ref&gt; The US [[Food and Drug Administration]] (FDA) approved the first [[Point-of-care testing|point-of-care test]] on 21 March 2020 for use at the end of that month.&lt;ref&gt;{{cite press release |title=Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic |date=21 March 2020 |publisher=U.S. [[Food and Drug Administration]] (FDA) |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic |access-date=22 March 2020 |archive-url=https://web.archive.org/web/20200321224700/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic |archive-date=21 March 2020 |url-status=live}}&lt;/ref&gt; The absence or presence of COVID-19 signs and symptoms alone is not reliable enough for an accurate diagnosis.&lt;ref&gt;{{cite journal | vauthors = Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Dittrich S, Domen J, Horn SR, Van den Bruel A | display-authors = 6 | title = Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease | journal = The Cochrane Database of Systematic Reviews | volume = 7 | pages = CD013665 | date = July 2020 | pmid = 32633856 | pmc = 7386785 | doi = 10.1002/14651858.CD013665 | s2cid = 220384495 }}&lt;/ref&gt; Different clinical scores were created based on symptoms, laboratory parameters and imaging to determine patients with probable SARS-CoV-2 infection or more severe stages of COVID-19.&lt;ref&gt;{{cite journal | vauthors = Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo H, Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J | display-authors = 6 | title = Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19 | journal = JAMA Internal Medicine | volume = 180 | issue = 8 | pages = 1081–1089 | date = August 2020 | pmid = 32396163 | doi = 10.1001/jamainternmed.2020.2033 | pmc = 7218676 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Levenfus I, Ullmann E, Battegay E, Schuurmans MM | title = Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score | journal = The Brazilian Journal of Infectious Diseases | pages = S1413867020301021 | date = August 2020 | pmid = 32828735 | doi = 10.1016/j.bjid.2020.07.003 | pmc = 7440000 | url = https://www.bjid.org.br/en-triage-tool-for-suspected-covid-19-avance-S1413867020301021 }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[File:20200410 Flatten the curve, raise the line - pandemic (English).gif|thumb|upright=1.5|Progressively stronger mitigation efforts to reduce the number of active cases at any given time—"[[flattening the curve]]"—allows healthcare services to better manage the same volume of patients.&lt;ref&gt;{{cite web |last=Wiles |first=Siouxsie |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |author-link=Siouxsie Wiles |title=The three phases of Covid-19&amp;nbsp;– and how we can make it manageable |url=https://thespinoff.co.nz/society/09-03-2020/the-three-phases-of-covid-19-and-how-we-can-make-it-manageable/ |website=The Spinoff |access-date=9 March 2020 |date=9 March 2020 |archive-url=https://web.archive.org/web/20200327120015/https://thespinoff.co.nz/society/09-03-2020/the-three-phases-of-covid-19-and-how-we-can-make-it-manageable/ |archive-date=27 March 2020 |url-status=live}}&lt;/ref&gt;&lt;ref name="Lancet2020Flatten"&gt;{{cite journal | vauthors = Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD | title = How will country-based mitigation measures influence the course of the COVID-19 epidemic? | journal = Lancet | volume = 395 | issue = 10228 | pages = 931–934 | date = March 2020 | pmid = 32164834 | pmc = 7158572 | doi = 10.1016/S0140-6736(20)30567-5 | quote = A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies. | doi-access = free }}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://www.vox.com/2020/3/10/21171481/coronavirus-us-cases-quarantine-cancellation|title=How canceled events and self-quarantines save lives, in one chart|first=Eliza|last=Barclay |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=10 March 2020|website=Vox|access-date=12 March 2020|archive-url=https://web.archive.org/web/20200312161852/https://www.vox.com/2020/3/10/21171481/coronavirus-us-cases-quarantine-cancellation|archive-date=12 March 2020|url-status=live}}&lt;/ref&gt; Likewise, progressively greater increases in healthcare capacity—called ''raising the line''—such as by increasing bed count, personnel, and equipment, helps to meet increased demand.&lt;ref name="Vox_20200407"&gt;{{cite web |last1=Barclay |first1=Eliza |last2=Scott |first2=Dylan |last3=Animashaun |first3=Animashaun |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=The US doesn't just need to flatten the curve. It needs to "raise the line." |url=https://www.vox.com/2020/4/7/21201260/coronavirus-usa-chart-mask-shortage-ventilators-flatten-the-curve |work=Vox |date=7 April 2020 |archive-url=https://web.archive.org/web/20200407155950/https://www.vox.com/2020/4/7/21201260/coronavirus-usa-chart-mask-shortage-ventilators-flatten-the-curve |archive-date=7 April 2020 |url-status=live}}&lt;/ref&gt;]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[File:20200409 Pandemic resurgence - effect of inadequate mitigation.gif|thumb|upright=1.5|Mitigation attempts that are inadequate in strictness or duration—such as premature relaxation of distancing rules or stay-at-home orders—can allow a resurgence after the initial surge and mitigation.&lt;ref name="Lancet2020Flatten" /&gt;&lt;ref name="Wiles"&gt;{{cite web |last=Wiles |first=Siouxsie |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means |url=https://thespinoff.co.nz/society/14-03-2020/after-flatten-the-curve-we-must-now-stop-the-spread-heres-what-that-means/ |website=The Spinoff |access-date=13 March 2020 |date=14 March 2020 |archive-url=https://web.archive.org/web/20200326232315/https://thespinoff.co.nz/society/14-03-2020/after-flatten-the-curve-we-must-now-stop-the-spread-heres-what-that-means/ |archive-date=26 March 2020 |url-status=live}}&lt;/ref&gt;]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>A [[COVID-19 vaccine]] is not expected until 2021 at the earliest.&lt;ref&gt;{{cite web |url=https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away |title=Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus |website=Science Alert |first1=Rob |last1=Grenfell |first2=Trevor |last2=Drew |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=17 February 2020 |access-date=26 February 2020 |archive-url=https://web.archive.org/web/20200228010631/https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away |archive-date=28 February 2020 |url-status=live}}&lt;/ref&gt; The US [[National Institutes of Health]] guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial.&lt;ref name="NIHGuidelines2020" /&gt;&lt;ref name="Sanders20202" /&gt; Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the [[epidemic curve|curve]]".&lt;ref name="Lancet2020Flatten" /&gt; This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.&lt;ref name="Lancet2020Flatten" /&gt;&lt;ref name="Wiles" /&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.&lt;ref name="CDC042020"&gt;{{cite web|date=28 June 2020|title=Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission|work=U.S. [[Centers for Disease Control and Prevention]] (CDC) |url=https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html|access-date=}}&lt;/ref&gt;&lt;ref name="CDC-Prevention &amp; Treatment"&gt;{{cite web |url=https://www.cdc.gov/coronavirus/about/prevention.html |vauthors=((Centers for Disease Control and Prevention)) |title=Coronavirus Disease 2019 (COVID-19): Prevention &amp; Treatment |date=3 February 2020 |access-date=10 February 2020 |archive-url=https://web.archive.org/web/20191215193934/https://www.cdc.gov/coronavirus/about/prevention.html |archive-date=15 December 2019 |url-status=live |author-link=Centers for Disease Control and Prevention}}&lt;/ref&gt;&lt;ref name="WHO Advice for Public"&gt;{{cite web |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public |title=Advice for Public |vauthors=((World Health Organization)) |access-date=10 February 2020 |archive-url=https://web.archive.org/web/20200126025750/https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public |archive-date=26 January 2020 |url-status=live |author-link=World Health Organization }}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://www.npr.org/sections/goatsandsoda/2020/03/17/814221111/my-hand-washing-song-readers-offer-lyrics-for-a-20-second-scrub|title=My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub|website=NPR.org|access-date=20 March 2020|archive-url=https://web.archive.org/web/20200320145553/https://www.npr.org/sections/goatsandsoda/2020/03/17/814221111/my-hand-washing-song-readers-offer-lyrics-for-a-20-second-scrub|archive-date=20 March 2020|url-status=live}}&lt;/ref&gt; Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.&lt;ref name="CDC2020IfSick"&gt;{{cite web|date=5 April 2020|title=What to Do if You Are Sick|url=https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html|url-status=live|archive-url=https://web.archive.org/web/20200214153016/https://www.cdc.gov/coronavirus/2019-ncov/about/steps-when-sick.html|archive-date=14 February 2020|access-date=24 April 2020|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|vauthors=((Centers for Disease Control and Prevention))}}&lt;/ref&gt;&lt;ref&gt;{{cite web|date=10 March 2020|title=Coronavirus Disease 2019 (COVID-19)&amp;nbsp;– Prevention &amp; Treatment|url=https://www.cdc.gov/coronavirus/2019-ncov/about/prevention.html|url-status=live|archive-url=https://web.archive.org/web/20200311163637/https://www.cdc.gov/coronavirus/2019-ncov/about/prevention.html|archive-date=11 March 2020|access-date=11 March 2020|work=U.S. [[Centers for Disease Control and Prevention]] (CDC)}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[Social distancing]] strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings.&lt;ref name="JHUSocialDistancing"&gt;{{cite web |first=Lisa Lockerd |last=Maragakis |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Coronavirus, Social Distancing and Self Quarantine |url=https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-social-distancing-and-self-quarantine |website=www.hopkinsmedicine.org |publisher=Johns Hopkins University |access-date=18 March 2020 |archive-url=https://web.archive.org/web/20200318012357/https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-social-distancing-and-self-quarantine |archive-date=18 March 2020 |url-status=live}}&lt;/ref&gt; Distancing guidelines also include that people stay at least {{Convert|2|metre|feet|abbr=}} apart.&lt;ref&gt;{{cite news|last=Parker-Pope|first=Tara |author-link=Tara Parker-Pope |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |url=https://www.nytimes.com/2020/03/19/well/live/coronavirus-quarantine-social-distancing.html|title=Deciding How Much Distance You Should Keep|date=19 March 2020|work=[[The New York Times]]|access-date=20 March 2020|issn=0362-4331|archive-url=https://web.archive.org/web/20200320003705/https://www.nytimes.com/2020/03/19/well/live/coronavirus-quarantine-social-distancing.html|archive-date=20 March 2020|url-status=live}}&lt;/ref&gt; After the implementation of [[social distancing]] and [[Shelter in place|stay-at-home]] orders, many regions have been able to sustain an effective transmission rate ("R&lt;sub&gt;t&lt;/sub&gt;") of less than one, meaning the disease is in remission in those areas.&lt;ref&gt;{{cite web |last1=Systrom |first1=Kevin |last2=Krieger |first2=Mike |last3=O'Rourke |first3=Ryan |last4=Stein |first4=Robby |first5=Frank |last5=Dellaert |first6=Adam |last6=Lerer |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=R&lt;sub&gt;t&lt;/sub&gt; Covid-19 |url=https://rt.live/ |website=rt.live |access-date=19 April 2020 |date=11 April 2020}} Based on {{cite journal |vauthors=Bettencourt LM, Ribeiro RM |title=Real time bayesian estimation of the epidemic potential of emerging infectious diseases |journal=PLOS ONE |volume=3 |issue=5 |pages=e2185 |date=May 2008 |pmid=18478118 |pmc=2366072 |doi=10.1371/journal.pone.0002185 |bibcode=2008PLoSO...3.2185B}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>The WHO, the [[National Health Commission|Chinese National Health Commission]], and the United States' [[National Institutes of Health]] have published recommendations for taking care of people who are hospitalised with COVID-19.&lt;ref name="NIHGuidelines2020"&gt;{{cite web |title=COVID-19 Treatment Guidelines |url=https://covid19treatmentguidelines.nih.gov/introduction/ |website=www.nih.gov |publisher=National Institutes of Health |access-date=21 April 2020}}&lt;/ref&gt;&lt;ref name="Cheng2020"&gt;{{cite journal |vauthors=Cheng ZJ, Shan J |title=2019 Novel coronavirus: where we are and what we know |journal=Infection |volume=48 |issue=2 |pages=155–163 |date=April 2020 |pmid=32072569 |pmc=7095345 |doi=10.1007/s15010-020-01401-y |doi-access=free}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected|title=Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected|website=[[World Health Organization]] (WHO)|access-date=13 February 2020|archive-url=https://web.archive.org/web/20200131032122/https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected|archive-date=31 January 2020|url-status=live}}&lt;/ref&gt; [[Critical care medicine|Intensivists]] and [[Pulmonology|pulmonologists]] in the US have compiled treatment recommendations from various agencies into a free resource, the [[EMCrit|IBCC]].&lt;ref name="IBCC"&gt;{{cite book |last=Farkas |first=Josh |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=March 2020 |title=COVID-19&amp;nbsp;– The Internet Book of Critical Care |url=https://emcrit.org/ibcc/covid19/ |url-status=live |format=digital |type=Reference manual |location=USA |publisher=EMCrit |archive-url=https://web.archive.org/web/20200311195758/https://emcrit.org/ibcc/covid19/ |archive-date=11 March 2020 |access-date=13 March 2020}}&lt;/ref&gt;&lt;ref name="UPenn-IBCC"&gt;{{cite web |url=https://guides.library.upenn.edu/covid-19 |title=COVID19&amp;nbsp;– Resources for Health Care Professionals |publisher=[[Penn Libraries]] |date=11 March 2020 |access-date=13 March 2020 |archive-url=https://web.archive.org/web/20200314035631/https://guides.library.upenn.edu/covid-19 |archive-date=14 March 2020 |url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>| caption1 = The severity of diagnosed COVID-19 cases in China&lt;ref&gt;{{cite journal |last1=Roser |first1=Max |last2=Ritchie |first2=Hannah |last3=Ortiz-Ospina |first3=Esteban |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Coronavirus Disease (COVID-19) |url=https://ourworldindata.org/coronavirus |journal=Our World in Data |access-date=12 March 2020 |date=4 March 2020 |archive-url=https://web.archive.org/web/20200319171947/https://ourworldindata.org/coronavirus |archive-date=19 March 2020 |url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>| caption4 = The number of deaths vs total cases by country and approximate case fatality rate&lt;ref&gt;{{cite journal |last1=Roser |first1=Max |last2=Ritchie |first2=Hannah |last3=Ortiz-Ospina |first3=Esteban |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Coronavirus Disease (COVID-19) |url=https://ourworldindata.org/coronavirus |journal=Our World in Data |access-date=6 April 2020 |date=6 April 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[COVID-19 in pregnancy|Pregnant women]] may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like [[severe acute respiratory syndrome]] (SARS) and [[Middle East respiratory syndrome]] (MERS), but data for COVID-19 is lacking.&lt;ref&gt;{{cite journal | vauthors = Fang L, Karakiulakis G, Roth M | title = Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | journal = The Lancet. Respiratory Medicine | volume = 8 | issue = 4 | pages = e21 | date = April 2020 | pmid = 32171062 | pmc = 7118626 | doi = 10.1016/S0140-6736(20)30311-1 }}&lt;/ref&gt;&lt;ref name="CDC 2020children"&gt;{{cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/children-faq.html|title=Coronavirus Disease 2019 (COVID-19)|date=11 February 2020|website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |access-date=2 March 2020|archive-url=https://web.archive.org/web/20200302064104/https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/children-faq.html|archive-date=2 March 2020|url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Most critical respiratory [[Comorbidity|comorbidities]] according to the [[Centers for Disease Control and Prevention|CDC]], are: moderate or severe [[asthma]], pre-existing [[Chronic obstructive pulmonary disease|COPD]], [[pulmonary fibrosis]], [[cystic fibrosis]].&lt;ref&gt;{{Cite web |date=11 February 2020|title=Coronavirus Disease 2019 (COVID-19)|url=https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html|access-date=19 June 2020|website=Centers for Disease Control and Prevention}}&lt;/ref&gt; Evidence stemming from [[meta-analysis]] of several smaller research papers also suggests that smoking can be associated with worse patient outcomes.&lt;ref&gt;{{cite journal |vauthors=Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, Deng Y, Lin S |display-authors=6 |title=The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis |journal=Journal of Medical Virology |date=April 2020 |volume=92 |issue=10 |pages=1915–1921 |pmid=32293753 |pmc=7262275 |doi=10.1002/jmv.25889}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|title=Smoking and COVID-19|url=https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19|access-date=19 June 2020|website=[[World Health Organization]] (WHO)}}&lt;/ref&gt; When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms.&lt;ref&gt;{{cite web|title=Coronavirus Disease 2019 (COVID-19)|url=https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html|date=11 February 2020|website=[[Centers for Disease Control and Prevention]] (CDC) |access-date=4 May 2020}}&lt;/ref&gt; COVID-19 also poses a greater risk to people who [[Opioid use disorder|misuse opioids]] and [[Stimulant use disorder|methamphetamines]], insofar as their drug use may have caused lung damage.&lt;ref&gt;{{cite web|title=People who use drugs are more vulnerable to coronavirus. Here's what clinics are doing to help.|url=https://www.theadvocate.com/baton_rouge/news/coronavirus/article_f80cf77e-84fa-11ea-88d5-2b37dc9dd966.html|last=DeRobertis|first=Jacqueline |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=3 May 2020|website=The Advocate (Louisiana)|access-date=4 May 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>The virus is thought to be natural and has an [[Zoonosis|animal origin]],&lt;ref name="NM-20200317"&gt;{{cite journal |vauthors=Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF |title=The proximal origin of SARS-CoV-2 |journal=Nature Medicine |volume=26 |issue=4 |pages=450–452 |date=April 2020 |pmid=32284615 |pmc=7095063 |doi=10.1038/s41591-020-0820-9}}&lt;/ref&gt; through [[spillover infection]].&lt;ref&gt;{{cite web|url=https://nautil.us/issue/83/intelligence/the-man-who-saw-the-pandemic-coming|title=The Man Who Saw the Pandemic Coming|last=Berger|first=Kevin|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc|date=12 March 2020|website=Nautilus|access-date=16 March 2020|archive-url=https://web.archive.org/web/20200315180124/http://nautil.us/issue/83/intelligence/the-man-who-saw-the-pandemic-coming|archive-date=15 March 2020|url-status=live}}&lt;/ref&gt; The first known human infections were in [[Wuhan]], Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in ''[[The Lancet]]'', reported the earliest date of onset of symptoms as 1{{nbsp}}December 2019.&lt;ref name="WuMarch2020"&gt;{{cite journal|vauthors=Wu YC, Chen CS, Chan YJ|date=March 2020|title=The outbreak of COVID-19: An overview|journal=Journal of the Chinese Medical Association|volume=83|issue=3|pages=217–220|doi=10.1097/JCMA.0000000000000270|pmc=7153464|pmid=32134861}}&lt;/ref&gt;&lt;ref name="Wang24Jan2020"&gt;{{cite journal|vauthors=Wang C, Horby PW, Hayden FG, Gao GF|date=February 2020|title=A novel coronavirus outbreak of global health concern|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30185-9/abstract|journal=Lancet|volume=395|issue=10223|pages=470–473|doi=10.1016/S0140-6736(20)30185-9|pmc=7135038|pmid=31986257|doi-access=free}}&lt;/ref&gt;&lt;ref name="AutoDW-67"&gt;{{cite journal|last=Cohen|first=Jon|date=January 2020|title=Wuhan seafood market may not be source of novel virus spreading globally|url=https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally|journal=[[Science (journal)|Science]]|doi=10.1126/science.abb0611|doi-access=free |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; Official publications from the WHO reported the earliest onset of symptoms as 8{{nbsp}}December 2019.&lt;ref&gt;{{cite web|date=12 January 2020|title=Novel Coronavirus&amp;nbsp;– China|url=https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/|website=[[World Health Organization]] (WHO)}}&lt;/ref&gt; Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.&lt;ref&gt;{{cite news|last1=Kessler|first1=Glenn|date=17 April 2020|title=Trump's false claim that the WHO said the coronavirus was 'not communicable'|work=[[The Washington Post]]|url=https://www.washingtonpost.com/politics/2020/04/17/trumps-false-claim-that-who-said-coronavirus-was-not-communicable/|url-status=live|access-date=17 April 2020|archive-url=https://archive.today/20200417193804/https://www.washingtonpost.com/politics/2020/04/17/trumps-false-claim-that-who-said-coronavirus-was-not-communicable/|archive-date=17 April 2020|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt;&lt;ref&gt;{{cite news|last1=Kuo|first1=Lily|date=21 January 2020|title=China confirms human-to-human transmission of coronavirus|work=[[The Guardian]]|url=https://www.theguardian.com/world/2020/jan/20/coronavirus-spreads-to-beijing-as-china-confirms-new-cases|access-date=18 April 2020|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; According to official Chinese sources, these were mostly linked to the [[Huanan Seafood Wholesale Market]], which also sold live animals.&lt;ref name="characteristicsZH"&gt;{{cite journal|author1=Novel Coronavirus Pneumonia Emergency Response Epidemiology Team|date=February 2020|title=[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]|journal=Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|language=zh|volume=41|issue=2|pages=145–151|doi=10.3760/cma.j.issn.0254-6450.2020.02.003|pmid=32064853|s2cid=211133882}}&lt;/ref&gt; In May 2020, [[George F. Gao|George Gao]], the director of the [[Chinese Center for Disease Control and Prevention]], said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early [[Superspreader|superspreading event]], but it was not the site of the initial outbreak.&lt;ref&gt;{{cite news|last=Areddy|first=James T.|date=26 May 2020|title=China Rules Out Animal Market and Lab as Coronavirus Origin|work=[[The Wall Street Journal]]|url=https://www.wsj.com/articles/china-rules-out-animal-market-and-lab-as-coronavirus-origin-11590517508|accessdate=29 May 2020|url-access=subscription}}&lt;/ref&gt; Traces of the virus have been found in wastewater that was collected from [[Milan]] and [[Turin]], Italy, on 18 December 2019.&lt;ref&gt;{{cite news|last=Kelland|first=Kate|date=19 June 2020|title=Italy sewage study suggests COVID-19 was there in December 2019|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-italy-sewage/italy-sewage-study-suggests-covid-19-was-there-in-december-2019-idUSKBN23Q1J9|access-date=23 June 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>There are several theories about where the first case (the so-called [[Index case|patient zero]]) originated.&lt;ref name="patientZero"&gt;{{cite news|last1=Duarte|first1=Fernando|date=24 February 2020|title=As the cases of coronavirus increase in China and around the world, the hunt is on to identify "patient zero".|work=BBC News Online|url=https://www.bbc.com/future/article/20200221-coronavirus-the-harmful-hunt-for-covid-19s-patient-zero|access-date=22 March 2020|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; According to an unpublicised report from the Chinese government, the first case can be traced back to 17 November 2019; the person was a 55-year-old citizen in the Hubei province. There were four men and five women reported to be infected in November, but none of them were "patient zero". By December 2019, the spread of infection was almost entirely driven by human-to-human transmission.&lt;ref name="Epidemiology2020Feb17"&gt;{{cite journal|vauthors=Yanping Z, et al.|collaboration=The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team|title=The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)&amp;nbsp;– China, 2020|url=http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51|journal=China CDC Weekly|volume=2|issue=8|pages=113–122|date=17 February 2020|publisher=[[Chinese Center for Disease Control and Prevention]]|doi=10.46234/ccdcw2020.032|access-date=18 March 2020|archive-url=https://web.archive.org/web/20200219142101/http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51|archive-date=19 February 2020|url-status=live|doi-access=free}}&lt;/ref&gt;&lt;ref name="Heymann Shindo 2020 pp. 542–45"&gt;{{cite journal |vauthors=Heymann DL, Shindo N |title=COVID-19: what is next for public health? |journal=Lancet |volume=395 |issue=10224 |pages=542–545 |date=February 2020 |pmid=32061313 |doi=10.1016/S0140-6736(20)30374-3 |doi-access=free}}&lt;/ref&gt; The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December&lt;ref&gt;{{Cite web|last=March 2020|first=Jeanna Bryner-Live Science Editor-in-Chief 14|title=1st known case of coronavirus traced back to November in China|url=https://www.livescience.com/first-case-coronavirus-found.html|access-date=31 May 2020|website=livescience.com}}&lt;/ref&gt; and at least 266 by 31 December.&lt;ref&gt;{{Cite web|last=Politics|first=Canadian|date=8 April 2020|title=The birth of a pandemic: How COVID-19 went from Wuhan to Toronto {{!}} National Post|url=https://nationalpost.com/news/politics/the-birth-of-a-pandemic-how-covid-19-went-from-wuhan-to-toronto|access-date=31 May 2020}}&lt;/ref&gt; On 24 December, [[Wuhan Central Hospital]] sent a [[bronchoalveolar lavage fluid]] (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus.&lt;ref name="caixintrace"&gt;{{Cite news|author=高昱|date=26 February 2020|title=独家 {{!}} 新冠病毒基因测序溯源：警报是何时拉响的|language=zh|trans-title=Exclusive {{!}} Tracing the New Coronavirus gene sequencing: when did the alarm sound|work=[[Caixin]]|url=http://china.caixin.com/2020-02-26/101520972.html|url-status=dead|access-date=1 March 2020|archive-url=https://web.archive.org/web/20200227094018/http://china.caixin.com/2020-02-26/101520972.html|archive-date=27 February 2020}}&lt;/ref&gt; A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December.&lt;ref&gt;{{Cite web|author1=路子康|title=最早上报疫情的她，怎样发现这种不一样的肺炎|url=https://news.china.com/zw/news/13000776/20200209/37780703.html|archive-url=https://web.archive.org/web/20200302165302/https://news.china.com/zw/news/13000776/20200209/37780703.html|archive-date=2 March 2020|accessdate=11 February 2020|website=中国网新闻|location=北京|language=zh-cn}}&lt;/ref&gt; On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for [[SARS]], causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. That evening, the Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause".&lt;ref name="promedmail6864153"&gt;{{cite web|title=Undiagnosed pneumonia&amp;nbsp;– China (HU): RFI|url=https://promedmail.org/promed-post/?id=6864153|accessdate=7 May 2020|website=ProMED Mail|publisher=ProMED}}&lt;/ref&gt; Eight of these doctors, including [[Li Wenliang]] (punished on 3{{nbsp}}January),&lt;ref name="siStf"&gt;{{cite news|date=7 February 2020|title='Hero who told the truth': Chinese rage over coronavirus death of whistleblower doctor|work=[[The Guardian]]|url=https://www.theguardian.com/global-development/2020/feb/07/coronavirus-chinese-rage-death-whistleblower-doctor-li-wenliang}}&lt;/ref&gt; were later admonished by the police for spreading false rumours, and another, [[Ai Fen]], was reprimanded by her superiors for raising the alarm.&lt;ref name="20200311theguardian"&gt;{{cite news|last1=Kuo|first1=Lily|date=11 March 2020|title=Coronavirus: Wuhan doctor speaks out against authorities|work=The Guardian|location=London|url=https://www.theguardian.com/world/2020/mar/11/coronavirus-wuhan-doctor-ai-fen-speaks-out-against-authorities|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>On 31 January 2020, Italy had its first confirmed cases, two tourists from China.&lt;ref name="Corriere_20Jan"&gt;{{cite web|date=31 January 2020|title=Coronavirus: Primi due casi in Italia|trans-title=Coronavirus: First two cases in Italy|url=https://www.corriere.it/cronache/20_gennaio_30/coronavirus-italia-corona-9d6dc436-4343-11ea-bdc8-faf1f56f19b7.shtml|access-date=31 January 2020|work=Corriere della sera|language=it}}&lt;/ref&gt; As of 13 March 2020, the [[World Health Organization]] (WHO) considered Europe the active centre of the pandemic.&lt;ref name="nypost20200313"&gt;{{cite news|last1=Fredericks|first1=Bob|date=13 March 2020|title=WHO says Europe is new epicenter of coronavirus pandemic|work=[[New York Post]]|url=https://nypost.com/2020/03/13/who-says-europe-is-new-epicenter-of-coronavirus-pandemic/|accessdate=9 May 2020|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; On 19 March 2020, Italy overtook China as the country with the most deaths.&lt;ref name="sky11960412"&gt;{{cite web|title=Coronavirus: Number of COVID-19 deaths in Italy surpasses China as total reaches 3,405|url=https://news.sky.com/story/coronavirus-number-of-covid-19-deaths-in-italy-surpasses-china-as-total-reaches-3-405-11960412|accessdate=7 May 2020|publisher=Sky News}}&lt;/ref&gt; By 26 March, the United States had overtaken China and Italy with the highest number of confirmed cases in the world.&lt;ref name="NYT-20200326"&gt;{{cite news|last1=McNeil Jr.|first1=Donald G.|author-link=Donald McNeil Jr.|date=26 March 2020|title=The U.S. Now Leads the World in Confirmed Coronavirus Cases|work=[[The New York Times]]|url=https://www.nytimes.com/2020/03/26/health/usa-coronavirus-cases.html|access-date=27 March 2020|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; Research on [[Severe acute respiratory syndrome coronavirus 2|coronavirus genomes]] indicates the majority of COVID-19 cases in [[COVID-19 pandemic in New York (state)|New York]] came from European travellers, rather than directly from China or any other Asian country.&lt;ref name="20200408nytimes"&gt;{{cite news|date=8 April 2020|title=Studies Show N.Y. Outbreak Originated in Europe|work=[[The New York Times]]|url=https://www.nytimes.com/2020/04/08/us/coronavirus-live-updates.html}}&lt;/ref&gt; Retesting of prior samples found a person in France who had the virus on 27 December 2019&lt;ref name="France-retest"&gt;{{cite news|last1=Irish|first1=John|date=4 May 2020|title=After retesting samples, French hospital discovers COVID-19 case from December|agency=[[Reuters]]|editor-last=Lough|editor-first=Richard|url=https://www.reuters.com/article/us-health-coronavirus-france-idUSKBN22G20L|access-date=4 May 2020|editor2-last=Graff|editor2-first=Peter|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt;&lt;ref name=":22"&gt;{{cite journal|vauthors=Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y|date=3 May 2020|title=SARS-COV-2 was already spreading in France in late December 2019|journal=International Journal of Antimicrobial Agents|volume=55|issue=6|page=106006|doi=10.1016/j.ijantimicag.2020.106006|pmc=7196402|pmid=32371096}}&lt;/ref&gt; and a person in the United States who died from the disease on 6{{nbsp}}February 2020.&lt;ref name="PBS-2wks"&gt;{{cite web|date=22 April 2020|title=2 died with coronavirus weeks before 1st U.S. virus death|url=https://www.pbs.org/newshour/nation/2-died-with-coronavirus-weeks-before-1st-u-s-virus-death|access-date=23 April 2020|website=PBS NewsHour}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>On 11 June 2020, after 55 days without a locally transmitted case,&lt;ref name=":42"&gt;{{Cite web|last=|first=|date=16 June 2020|title=Beijing Covid-19 outbreak puts food markets back in infection focus|url=https://www.scmp.com/news/china/society/article/3089161/beijing-covid-19-outbreak-puts-food-markets-back-infection-focus|url-status=live|archive-url=https://web.archive.org/web/20200616040222/https://www.scmp.com/news/china/society/article/3089161/beijing-covid-19-outbreak-puts-food-markets-back-infection-focus|archive-date=16 June 2020|access-date=17 June 2020|website=South China Morning Post}}&lt;/ref&gt; Beijing reported the first COVID-19 case, followed by two more cases on 12 June.&lt;ref&gt;{{Cite web|last=|first=|date=|title=北京连续确诊3例新冠患者 新发地批发市场暂停营业|url=http://www.caixin.com/2020-06-12/101566522.html|url-status=live|archive-url=https://web.archive.org/web/20200613014454/http://www.caixin.com/2020-06-12/101566522.html|archive-date=13 June 2020|access-date=17 June 2020|website=www.caixin.com}}&lt;/ref&gt; By 15 June 79 cases were officially confirmed.&lt;ref&gt;{{Cite web|first=Nectar |last=Gan|title=China's new coronavirus outbreak sees Beijing adopt 'wartime' measures|url=https://www.cnn.com/2020/06/15/asia/coronavirus-beijing-outbreak-intl-hnk/index.html|url-status=live|archive-url=https://web.archive.org/web/20200616001340/https://www.cnn.com/2020/06/15/asia/coronavirus-beijing-outbreak-intl-hnk/index.html|archive-date=16 June 2020|access-date=17 June 2020|website=CNN |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; Most of these patients went to [[Xinfadi Market|Xinfadi Wholesale Market]].&lt;ref name=":42" /&gt;&lt;ref&gt;{{Cite web|title=Beijing logs record 36 COVID-19 cases, linked to market cluster|url=https://www.channelnewsasia.com/news/asia/covid-19-cases-china-beijing-market-cluster-12833874|access-date=17 June 2020|website=CNA}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Several measures are commonly used to quantify mortality.&lt;ref&gt;{{cite book|vauthors=((Centers for Disease Control and Prevention)) |chapter-url=https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section3.html|title=Principles of Epidemiology in Public Health Practice |edition=Third |chapter=Lesson 3: Measures of Risk Section 3: Mortality Frequency Measures |date=May 2012|publisher=U.S. [[Centers for Disease Control and Prevention]] (CDC)|access-date=28 March 2020|archive-url=https://web.archive.org/web/20200228150607/https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section3.html|archive-date=28 February 2020|url-status=live |id=No. SS1978}}&lt;/ref&gt; These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.&lt;ref&gt;{{cite web |url=https://ourworldindata.org/covid-mortality-risk |title=What do we know about the risk of dying from COVID-19? |last1=Ritchie |first1=Hannah |last2=Roser |first2=Max |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=25 March 2020 |editor-last=Chivers |editor-first=Tom |website=[[Our World in Data]] |url-status=live |access-date=28 March 2020 |archive-url=https://web.archive.org/web/20200328192730/https://ourworldindata.org/covid-mortality-risk |archive-date=28 March 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing.&lt;ref name="Hawks2020" /&gt;&lt;ref&gt;{{cite web |first=David |last=Waldstein |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=To Fight Virus in Prisons, C.D.C. Suggests More Screenings |website=[[The New York Times]] |date=6 May 2020 |url=https://www.nytimes.com/2020/05/06/health/coronavirus-prisons-cdc.html |access-date=14 May 2020}}&lt;/ref&gt; In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.&lt;ref name="Hawks2020"&gt;{{cite journal |vauthors=Hawks L, Woolhandler S, McCormick D |title=COVID-19 in Prisons and Jails in the United States |journal=JAMA Internal Medicine |date=April 2020 |volume=180 |issue=8 |pages=1041–1042 |pmid=32343355 |doi=10.1001/jamainternmed.2020.1856 |doi-access=free}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>The CDC estimated for planning purposes that the IFR was 0.65% and that 40% of infected individuals are asymptomatic, suggesting a fatality rate among those who are symptomatic of 1.1% (.65/60) (as of 10 July).&lt;ref&gt;{{cite web |title=Coronavirus Disease 2019 (COVID-19) |url=https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html |website=U.S. [[Centers for Disease Control and Prevention]] (CDC) |accessdate=22 May 2020 |date=11 February 2020|archive-url=https://web.archive.org/web/20200831104408/https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html |archive-date=31 August 2020 }}&lt;/ref&gt;&lt;ref&gt;{{Cite web|last1=Gan|first1=Nectar|last2=McKeehan|first2=Brett | name-list-<ins class="diffchange diffchange-inline">style</ins> = vanc |date=11 July 2020|title=CDC now estimates that 40% of people infected with Covid-19 don't have any symptoms |url= https://edition.cnn.com/world/live-news/coronavirus-pandemic-07-11-20-intl/h_d6a63735c82f708ffdcff33082da393b |access-date=18 July 2020|website=CNN }}&lt;/ref&gt; Studies incorporating data from broad serology testing in Europe show IFR estimates converging at approximately 0.5–1%.&lt;ref&gt;{{Cite web|title=Estimating mortality from COVID-19|url=https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19|access-date=21 September 2020|website=www.who.int|language=en}}&lt;/ref&gt; According to the [[University of Oxford]] [[Centre for Evidence-Based Medicine]] (CEBM), random antibody testing in Germany suggested a national IFR of 0.4% (0.1% to 0.9%).&lt;ref name="cebm-global-cf"&gt;{{cite web|date=17 March 2020|title=Global Covid-19 Case Fatality Rates|url=https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/|access-date=10 April 2020|website=[[Centre for Evidence-Based Medicine]]}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://towardsdatascience.com/gangelt-a-representative-study-on-the-lethality-of-covid-19-5d877dbd6e55 |archive-url=https://web.archive.org/web/20200503120644/https://towardsdatascience.com/gangelt-a-representative-study-on-the-lethality-of-covid-19-5d877dbd6e55?gi=d7fb6f1c96ba |archive-date=3 May 2020 |title=Gangelt–A representative study on the lethality of COVID-19|last=Haake|first=Daniel|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc|date=24 April 2020|website=Medium|access-date=27 April 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|title=Antibody surveys suggesting vast undercount of coronavirus infections may be unreliable|last=Vogel |first=Gretchen |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=21 April 2020|journal=Science |doi=10.1126/science.abc3831 |doi-access=free}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10{{nbsp}}July, in New York City, with a population of 8.4{{nbsp}}million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population).&lt;ref&gt;{{cite web |title=COVID-19: Data |url=https://www1.nyc.gov/site/doh/covid/covid-19-data.page |publisher=City of New York}}&lt;/ref&gt; May antibody testing in New York City suggested an IFR of 0.9%.&lt;ref&gt;{{cite ssrn|title=SARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) Implied by the Serology, Antibody, Testing in New York City|last=Wilson|first=Linus|date=May 2020|ssrn=3590771}}&lt;/ref&gt; In [[Province of Bergamo|Bergamo province]], 0.6% of the population has died.&lt;ref&gt;{{cite web|url=https://medium.com/bccp-uc-berkeley/how-deadly-is-covid-19-data-science-offers-answers-from-italy-mortality-data-58abedf824cf|title=How deadly is COVID-19? Data Science offers answers from Italy mortality data.|last=Modi|first=Chirag |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=21 April 2020 |website=Medium |access-date=23 April 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>In the U.K., a greater proportion of deaths due to COVID-19 have occurred in those of a [[Black British people|Black]], [[British Asian|Asian]], and other ethnic minority background.&lt;ref&gt;{{Cite web|date=9 June 2020|title=How coronavirus deaths in the UK compare by race and ethnicity|url=https://www.independent.co.uk/news/uk/home-news/coronavirus-death-toll-uk-race-white-black-asian-bame-ethnicity-cases-a9557076.html|access-date=10 June 2020|website=The Independent}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|title=Emerging findings on the impact of COVID-19 on black and minority ethnic people|url=https://www.health.org.uk/news-and-comment/charts-and-infographics/emerging-findings-on-the-impact-of-covid-19-on-black-and-min|access-date=10 June 2020|website=The Health Foundation}}&lt;/ref&gt;&lt;ref&gt;{{cite news |last1=Butcher |first1=Benjamin |last2=Massey|first2=Joel |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=9 June 2020|title=Why are more BAME people dying from coronavirus?|work=BBC News Online |url=https://www.bbc.com/news/uk-52219070 |access-date=10 June 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus",&lt;ref&gt;{{cite web|url=https://www.npr.org/sections/health-shots/2020/01/24/799208865/a-second-u-s-case-of-wuhan-coronavirus-is-confirmed|title=2nd U.S. Case Of Wuhan Coronavirus Confirmed|website=NPR.org|access-date=4 April 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite news|last=McNeil Jr |first=Donald G. |author-link=Donald McNeil Jr. |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |url=https://www.nytimes.com/2020/02/02/health/coronavirus-pandemic-china.html|title=Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say|date=2 February 2020|work=[[The New York Times]]|access-date=4 April 2020|issn=0362-4331}}&lt;/ref&gt;&lt;ref&gt;{{cite news|url=https://www.cnn.com/2020/02/05/asia/wuhan-coronavirus-update-death-toll-spike-intl-hnk/index.html|title=Wuhan coronavirus deaths spike again as outbreak shows no signs of slowing|last=Griffiths|first=James |website=CNN|access-date=4 April 2020 |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc}}&lt;/ref&gt; with the disease sometimes called "Wuhan pneumonia".&lt;ref&gt;{{cite journal |vauthors=Jiang S, Xia S, Ying T, Lu L |title=A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome |journal=Cellular &amp; Molecular Immunology |volume=17 |issue=5 |pages=554 |date=May 2020 |pmid=32024976 |doi=10.1038/s41423-020-0372-4 |pmc=7091741 |doi-access=free}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY |display-authors=6 |title=A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster |journal=Lancet |volume=395 |issue=10223 |pages=514–523 |date=February 2020 |pmid=31986261 |pmc=7159286 |doi=10.1016/S0140-6736(20)30154-9 |doi-access=free}}&lt;/ref&gt; In the past, many diseases have been named after geographical locations, such as the [[Spanish flu]],&lt;ref&gt;{{cite journal |last1=Shablovsky |first1=Suzanne |s2cid=44116811 |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=The legacy of the Spanish flu |journal=Science |date=22 September 2017 |volume=357 |issue=6357 |pages=1245 |doi=10.1126/science.aao4093 |bibcode=2017Sci...357.1245S |url=https://science.sciencemag.org/content/357/6357/1245 |issn=0036-8075}}&lt;/ref&gt; [[Middle East Respiratory Syndrome]], and [[Zika virus]].&lt;ref name="Nature Stop"&gt;{{cite news |title=Stop the coronavirus stigma now |url=https://www.nature.com/articles/d41586-020-01009-0 |access-date=16 April 2020 |work=Nature |date=7 April 2020 |pages=165 |doi=10.1038/d41586-020-01009-0}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>In January 2020, the [[World Health Organization]] recommended 2019-nCov&lt;ref&gt;{{cite web|url=https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf|title=Novel Coronavirus (2019-nCoV) Situation Report&amp;nbsp;– 1 |date=21 January 2020|website=[[World Health Organization]] (WHO) |access-date=}}&lt;/ref&gt; and 2019-nCoV acute respiratory disease&lt;ref&gt;{{cite web|url=https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200130-sitrep-10-ncov.pdf|title=Novel Coronavirus(2019-nCoV) Situation Report&amp;nbsp;– 10 |date=30 January 2020|website=[[World Health Organization]] (WHO) |access-date=}}&lt;/ref&gt; as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent [[social stigma]].&lt;ref&gt;{{cite news |title=Novel coronavirus named 'Covid-19': WHO |url=https://www.todayonline.com/world/wuhan-novel-coronavirus-named-covid-19-who |access-date=11 February 2020 |publisher=TODAYonline |archive-url=https://archive.today/20200321085608/https://www.todayonline.com/world/wuhan-novel-coronavirus-named-covid-19-who |archive-date=21 March 2020 |url-status=live}}&lt;/ref&gt;&lt;ref name="veconomist"&gt;{{cite news |title=The coronavirus spreads racism against&amp;nbsp;– and among&amp;nbsp;– ethnic Chinese |url=https://www.economist.com/china/2020/02/17/the-coronavirus-spreads-racism-against-and-among-ethnic-chinese |work=[[The Economist]] |date=17 February 2020 |access-date=17 February 2020 |archive-url=https://web.archive.org/web/20200217223902/https://www.economist.com/china/2020/02/17/the-coronavirus-spreads-racism-against-and-among-ethnic-chinese |archive-date=17 February 2020 |url-status=live }}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://apps.who.int/iris/bitstream/handle/10665/163636/WHO_HSE_FOS_15.1_eng.pdf|title=World Health Organization Best Practices for the Naming of New Human Infectious Diseases |date=May 2015|website=[[World Health Organization]] (WHO) |access-date=}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>After the initial [[COVID-19 pandemic|outbreak]] of COVID-19, [[misinformation]] and [[disinformation]] regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.&lt;ref name="bbc_misinfo"&gt;{{cite news |url=https://www.bbc.com/news/blogs-trending-51271037 |title=China coronavirus: Misinformation spreads online about origin and scale |date=30 January 2020 |publisher=[[BBC News Online]] |access-date=10 February 2020 |archive-url=https://web.archive.org/web/20200204163412/https://www.bbc.com/news/blogs-trending-51271037 |archive-date=4 February 2020 |url-status=live}}&lt;/ref&gt;&lt;ref name="GUAR"&gt;{{cite newspaper |url=https://www.theguardian.com/world/2020/jan/31/bat-soup-dodgy-cures-and-diseasology-the-spread-of-coronavirus-bunkum |title=Bat soup, dodgy cures and 'diseasology': the spread of coronavirus misinformation |date=31 January 2020 |access-date=3 February 2020 |first=Josh |last=Taylor |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |newspaper=[[The Guardian]] |archive-url=https://web.archive.org/web/20200202141231/https://www.theguardian.com/world/2020/jan/31/bat-soup-dodgy-cures-and-diseasology-the-spread-of-coronavirus-bunkum |archive-date=2 February 2020 |url-status=live}}&lt;/ref&gt;&lt;ref name="RunningList"&gt;{{cite web |url=https://www.buzzfeednews.com/article/janelytvynenko/coronavirus-disinformation-spread |title=Here's A Running List Of Disinformation Spreading About The Coronavirus |website=Buzzfeed News |access-date=8 February 2020 |archive-url=https://web.archive.org/web/20200206212717/https://www.buzzfeednews.com/article/janelytvynenko/coronavirus-disinformation-spread |archive-date=6 February 2020 |url-status=dead}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Humans appear to be capable of spreading the virus to some other animals. A domestic cat in [[Liège]], Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive.&lt;ref&gt;{{cite web|url=https://www.brusselstimes.com/all-news/belgium-all-news/103003/coronavirus-belgian-woman-infected-her-cat/ |title=Coronavirus: Belgian cat infected by owner |publisher=Brusselstimes.com |date=27 March 2020 |access-date=12 April 2020}}&lt;/ref&gt; Tigers and lions at the [[Bronx Zoo]] in New York, United States, tested positive for the virus and showed symptoms of COVID-19, including a dry cough and loss of appetite.&lt;ref&gt;{{cite news |last=Goldstein |first=Joseph |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Bronx Zoo Tiger Is Sick With the Coronavirus |url=https://www.nytimes.com/2020/04/06/nyregion/bronx-zoo-tiger-coronavirus.html |website=[[The New York Times]] |date=6 April 2020 |access-date=9 April 2020}}&lt;/ref&gt; [[Mink]]s at two farms in the Netherlands also tested positive for COVID-19.&lt;ref&gt;{{cite web|url=https://www.foxnews.com/world/mink-netherlands-coronavirus-farm |title=Coronavirus hits Netherlands farm animals as minks test positive for virus |publisher=Fox News |date=26 April 2020|access-date=27 April 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>No medication or vaccine other than [[remdesivir]] is approved with the specific indication to treat the disease.&lt;ref name="LiDeClerq"&gt;{{cite journal |vauthors=Li G, De Clercq E |title=Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |journal=Nature Reviews. Drug Discovery |volume=19 |issue=3 |pages=149–150 |date=March 2020 |pmid=32127666 |doi=10.1038/d41573-020-00016-0 |doi-access=free}}&lt;/ref&gt; In Australia and the European Union, remdesivir (Veklury) is [[Indication (medicine)|indicated]] for the treatment of COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40&amp;nbsp;kg) with pneumonia requiring supplemental oxygen.&lt;ref&gt;{{cite web | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2020-PI-01927-1 | title=Australian Product Information – Veklury (Remdesivir) Powder For Injection | website=[[Therapeutic Goods Administration]] (TGA) | access-date=30 August 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite web | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2020-PI-01928-1 | title=Australian Product Information – Veklury (Remdesivir) Concentrate For Injection | website=[[Therapeutic Goods Administration]] (TGA) | access-date=30 August 2020}}&lt;/ref&gt;&lt;ref name="Veklury EPAR"&gt;{{cite web | title=Veklury EPAR | website=European Medicines Agency | date=23 June 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/veklury | access-date=30 August 2020}}&lt;/ref&gt; International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers.&lt;ref name="dhama"&gt;{{cite journal |vauthors=Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W |title=COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |journal=Human Vaccines &amp; Immunotherapeutics |pages=1232–1238 |date=March 2020 |volume=16 |issue=6 |pmid=32186952 |pmc=7103671 |doi=10.1080/21645515.2020.1735227 |doi-access=free}}&lt;/ref&gt;&lt;ref name="zhang2020"&gt;{{cite journal |vauthors=Zhang L, Liu Y |title=Potential interventions for novel coronavirus in China: A systematic review |journal=Journal of Medical Virology |volume=92 |issue=5 |pages=479–490 |date=May 2020 |pmid=32052466 |pmc=7166986 |doi=10.1002/jmv.25707}}&lt;/ref&gt; In March, the World Health Organization initiated the "[[Solidarity Trial]]" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.&lt;ref name="kai"&gt;{{cite journal |last1=Kupferschmidt |first1=Kai |last2=Cohen |first2=Jon |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=WHO launches global megatrial of the four most promising coronavirus treatments |journal=Science Magazine |date=22 March 2020 |url=https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments |access-date=27 March 2020|doi=10.1126/science.abb8497 |doi-access=free}}&lt;/ref&gt; The World Health Organization suspended hydroxychloroquine from its global drug trials for COVID-19 treatments on 26 May 2020 due to safety concerns. It had previously enrolled 3,500 patients from 17 countries in the Solidarity Trial.&lt;ref name=20200526nytimes&gt;{{cite web |url=https://www.nytimes.com/2020/05/26/world/coronavirus-news.html |title=Citing safety concerns, the W.H.O. paused tests of a drug Trump said he had taken |date=26 May 2020 |work=[[The New York Times]]}}&lt;/ref&gt; France, Italy and Belgium also banned the use of hydroxychloroquine as a COVID-19 treatment.&lt;ref&gt;{{cite web |url=https://www.cbsnews.com/news/france-bans-use-of-hydroxychloroquine-drug-touted-by-trump-to-treat-coronavirus/ |title=France bans use of hydroxychloroquine, drug touted by Trump, in coronavirus patients |date=27 May 2020 |publisher=CBS News}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission,&lt;ref&gt;{{cite journal | vauthors = Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM | title = Early dynamics of transmission and control of COVID-19: a mathematical modelling study | journal = The Lancet. Infectious Diseases | volume = 20 | issue = 5 | pages = 553–558 | date = May 2020 | pmid = 32171059 | pmc = 7158569 | doi = 10.1016/S1473-3099(20)30144-4 | doi-access = free }}&lt;/ref&gt; diagnosis and prognosis of infection,&lt;ref&gt;{{cite journal | vauthors = Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MM, Damen JA, Debray TP, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Kreuzberger N, Lohman A, Luijken K, Ma J, Andaur CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJ, Snell KI, Sperrin M, Spijker R, Steyerberg EW, Takada T, van Kuijk SM, van Royen FS, Wallisch C, Hooft L, Moons KG, van Smeden M | display-authors = 6 | title = Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal | journal = BMJ | volume = 369 | pages = m1328 | date = April 2020 | pmid = 32265220 | pmc = 7222643 | doi = 10.1136/bmj.m1328 | doi-access = free }}&lt;/ref&gt; estimation of the impact of interventions,&lt;ref&gt;{{cite journal | vauthors = Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, Colaneri M | title = Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy | journal = Nature Medicine | volume = 26 | issue = 6 | pages = 855–860 | date = June 2020 | pmid = 32322102 | pmc = 7175834 | doi = 10.1038/s41591-020-0883-7 | doi-access = free }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | vauthors = Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, Jit M, Klepac P | display-authors = 6 | title = The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study | journal = The Lancet. Public Health | volume = 5 | issue = 5 | pages = e261–e270 | date = May 2020 | pmid = 32220655 | pmc = 7158905 | doi = 10.1016/S2468-2667(20)30073-6 | doi-access = free }}&lt;/ref&gt; or allocation of resources.&lt;ref&gt;{{cite journal | vauthors = Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, Zhang C, Boyle C, Smith M, Phillips JP | display-authors = 6 | title = Fair Allocation of Scarce Medical Resources in the Time of Covid-19 | journal = The New England Journal of Medicine | volume = 382 | issue = 21 | pages = 2049–2055 | date = May 2020 | pmid = 32202722 | doi = 10.1056/NEJMsb2005114 | doi-access = free }}&lt;/ref&gt; Modelling studies are mostly based on epidemiological models,&lt;ref&gt;{{Cite journal |doi=10.1098/rspa.1927.0118 |volume=115 |issue=772 |pages=700–721 |title=A contribution to the mathematical theory of epidemics |journal=Proceedings of the Royal Society of London. Series A, Containing Papers of a Mathematical and Physical Character |year=1927 |bibcode=1927RSPSA.115..700K |doi-access=free| vauthors = Kermack WO, McKendrick AG }}&lt;/ref&gt; estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19,&lt;ref&gt;{{Cite journal |doi=10.1017/jfm.2020.330 |volume=894 |pages=–2 |last1=Mittal |first1=Rajat |last2=Ni |first2=Rui |last3=Seo |first3=Jung-Hee |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=The flow physics of COVID-19 |journal=Journal of Fluid Mechanics |year=2020 |arxiv=2004.09354 |bibcode=2020JFM...894F...2M |access-date=11 August 2020 |url=https://www.cambridge.org/core/product/identifier/S0022112020003304/type/journal_article |doi-access=free}}&lt;/ref&gt; retrofits of crowd movement models to study occupant exposure,&lt;ref&gt;{{cite journal | vauthors = Ronchi E, Lovreglio R | title = Exposed: An occupant exposure model for confined spaces to retrofit crowd models during a pandemic | journal = Safety Science | volume = 130 | pages = 104834 | date = October 2020 | pmid = 32834509 | pmc = 7373681 | doi = 10.1016/j.ssci.2020.104834 | arxiv = 2005.04007 | doi-access = free }}&lt;/ref&gt; mobility-data based models to investigate transmission,&lt;ref&gt;{{cite journal | vauthors = Badr HS, Du H, Marshall M, Dong E, Squire MM, Gardner LM | title = Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study | journal = The Lancet. Infectious Diseases | date = July 2020 | pmid = 32621869 | pmc = 7329287 | doi = 10.1016/S1473-3099(20)30553-3 | url = https://linkinghub.elsevier.com/retrieve/pii/S1473309920305533 | doi-access = free }}&lt;/ref&gt; or the use of macroeconomic models to assess the economic impact of the pandemic.&lt;ref&gt;{{cite journal |last1=McKibbin |first1=Warwick |last2=Roshen |first2=Fernando |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=The global macroeconomic impacts of COVID-19: Seven scenarios |journal=CAMA Working Paper |year=2020 |doi=10.2139/ssrn.3547729 |s2cid=216307705 |url=https://cama.crawford.anu.edu.au/sites/default/files/publication/cama_crawford_anu_edu_au/2020-03/19_2020_mckibbin_fernando_0.pdf}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. To minimise the harm from [[Misinformation related to the COVID-19 pandemic|misinformation]], medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to [[Retractions in academic publishing|retractions]] and other updates.&lt;ref&gt;{{cite web|url=http://www.covidliterature.ca/|title=Navigating the COVID-19 Evidence Landscape|last1=Bradley-Ridout|first1=Glyneva|last2=Fuller|first2=Kaitlin |last3=Gray|first3=Mikaela|last4=Nekolaichuk|first4=Erica |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=9 April 2020|publisher=University of Toronto Libraries—Gerstein Science Information Centre}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>At least 29 Phase II–IV efficacy trials in COVID-19 were concluded in March 2020, or scheduled to provide results in April from hospitals in China.&lt;ref name="milken"&gt;{{cite web |title=COVID-19 treatment and vaccine tracker |url=https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-21-20-2.pdf |publisher=Milken Institute |access-date=21 April 2020 |date=21 April 2020 |lay-url=https://milkeninstitute.org/covid-19-tracker}}&lt;/ref&gt;&lt;ref name="koch"&gt;{{cite web |first1=Selina |last1=Koch |first2=Winnie |last2=Pong |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=First up for COVID-19: nearly 30 clinical readouts before end of April |url=https://www.biocentury.com/article/304658 |publisher=BioCentury Inc. |access-date=1 April 2020 |date=13 March 2020}}&lt;/ref&gt; There are more than 300 active clinical trials underway as of April 2020.&lt;ref name="Sanders20202" /&gt; Seven trials were evaluating already approved treatments, including four studies on [[hydroxychloroquine]] or [[chloroquine]].&lt;ref name=koch/&gt; Repurposed [[antiviral drug]]s make up most of the research, with nine Phase{{nbsp}}III trials on remdesivir across several countries due to report by the end of April.&lt;ref name=milken/&gt;&lt;ref name=koch/&gt; Other candidates in trials include [[vasodilator]]s, [[corticosteroid]]s, [[immunotherapy|immune therapies]], [[lipoic acid]], [[bevacizumab]], and [[recombinant DNA|recombinant]] [[angiotensin-converting enzyme 2]].&lt;ref name=koch/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Several existing medications are being evaluated for the treatment of COVID-19,&lt;ref name="LiDeClerq" /&gt; including [[remdesivir]], [[chloroquine]], [[hydroxychloroquine]], [[lopinavir/ritonavir]], and lopinavir/ritonavir combined with [[Interferon-beta|interferon beta]].&lt;ref name=kai/&gt;&lt;ref&gt;{{cite web|url=https://news.un.org/en/story/2020/03/1059722|title=UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment|date=18 March 2020|website=UN News|access-date=23 March 2020|archive-url=https://web.archive.org/web/20200323101633/https://news.un.org/en/story/2020/03/1059722|archive-date=23 March 2020|url-status=live}}&lt;/ref&gt; There is tentative evidence for efficacy by remdesivir, and on 1{{nbsp}}May 2020, the United States [[Food and Drug Administration]] (FDA) gave the drug an [[emergency use authorization]] (EUA) for people hospitalized with severe COVID-19.&lt;ref&gt;{{Cite press release |date=4 May 2020|title=Coronavirus (COVI D-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment|work=U.S. [[Food and Drug Administration]] (FDA)|url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment|access-date=8 June 2020}}&lt;/ref&gt; On 28 August 2020, the FDA broadened the EUA for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID-19, irrespective of the severity of their disease.&lt;ref&gt;{{cite press release | title=COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 | website=U.S. [[Food and Drug Administration]] (FDA) | date=28 August 2020 | url=https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized | access-date=28 August 2020}} {{PD-notice}}&lt;/ref&gt;&lt;ref&gt;{{cite press release | title=Gilead's Investigational Antiviral Veklury (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19 | publisher=Gilead Sciences | via=Business Wire | date=28 August 2020 | url=https://www.businesswire.com/news/home/20200828005370/en/ | access-date=28 August 2020}}&lt;/ref&gt;&lt;ref name="FDA EUA Fact Sheet"&gt;{{cite web | title = FDA EUA Remdesivir Fact Sheet for Health Care Providers | url = https://www.fda.gov/media/137566/download | format = PDF | lay-url = https://www.fda.gov/media/137565/download | publisher = U.S. [[Food and Drug Administration]] (FDA) | date = 28 August 2020 | access-date = 28 August 2020}} {{PD-notice}}&lt;/ref&gt; [[Phase III clinical trials]] for several drugs{{which|date=September 2020}} are underway{{when|date=September 2020}} in several countries, including the US, China, and Italy.&lt;ref name="LiDeClerq" /&gt;&lt;ref name=milken/&gt;&lt;ref&gt;{{cite journal |last1=Beeching |first1=Nicholas J. |last2=Fletcher |first2=Tom E. |last3=Fowler |first3=Robert |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=2020 |title=BMJ Best Practices: COVID-19 |url=https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/COVID-19.pdf |url-status=live |journal=BMJ |access-date=11 March 2020 |archive-url=https://web.archive.org/web/20200222170544/https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/COVID-19.pdf |archive-date=22 February 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>There are mixed results as of 3 April 2020, as to the effectiveness of hydroxychloroquine as a treatment for COVID-19, with some studies showing little or no improvement.&lt;ref&gt;{{cite news |last1=Seley-Radtke |first1=Katherine |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County |url=https://theconversation.com/a-small-trial-finds-that-hydroxychloroquine-is-not-effective-for-treating-coronavirus-135484 |access-date=5 April 2020 |work=[[The Conversation (website)|The Conversation]] |date=3 April 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N |title=No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |language=fr |journal=Médecine et Maladies Infectieuses |volume=50 |issue=4 |pages=384 |date=June 2020 |pmid=32240719 |pmc=7195369 |doi=10.1016/j.medmal.2020.03.006}}&lt;/ref&gt; One study has shown an association between hydroxychloroquine or chloroquine use with higher death rates along with other side effects.&lt;ref&gt;{{Cite web |first1=Ariana Eunjung |last1=Cha |first2=Laurie |last2=McGinley |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Antimalarial drug touted by President Trump is linked to increased risk of death in coronavirus patients, study says |url=https://www.washingtonpost.com/health/2020/05/22/hydroxychloroquine-coronavirus-study/ |website=Washington Post|access-date=27 May 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=Mehra MR, Desai SS, Ruschitzka F, Patel AN |title=Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis |language=English |journal=Lancet |volume=0 |date=May 2020 |pmid=32450107 |pmc=7255293 |doi=10.1016/S0140-6736(20)31180-6 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/abstract |doi-access=free}}&lt;/ref&gt; A retraction of this study by its authors was published by ''The Lancet'' on 4{{nbsp}}June 2020.&lt;ref&gt;{{Cite journal |vauthors=Mehra MR, Desai SS, Ruschitzka F, Patel AN |date=4 June 2020|title=Retraction: "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis"|url=https://www.thelancet.com/lancet/article/s0140673620313246|journal=Lancet|volume=395|issue=10240|page=1820glish|doi=10.1016/S0140-6736(20)31324-6|pmid=32511943|pmc=7274621|doi-access=free}}&lt;/ref&gt; The studies of chloroquine and hydroxychloroquine with or without [[azithromycin]] have major limitations that have prevented the medical community from embracing these therapies without further study.&lt;ref name="Sanders20202" /&gt; On 15 June 2020, the FDA updated the fact sheets for the emergency use authorization of remdesivir to warn that using chloroquine or hydroxychloroquine with remdesivir may reduce the antiviral activity of remdesivir.&lt;ref&gt;{{cite press release |title=Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use |website=U.S. [[Food and Drug Administration]] (FDA) |date=15 June 2020 |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce |access-date=15 June 2020}} {{PD-notice}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>In June, initial results from a [[RECOVERY Trial|randomised trial]] in the United Kingdom showed that [[dexamethasone]] reduced mortality by one third for patients who are critically ill on ventilators and one fifth for those receiving supplemental oxygen.&lt;ref&gt;{{cite news |last1=Boseley |first1=Sarah |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=Recovery trial for Covid-19 treatments: what we know so far |url= https://www.theguardian.com/world/2020/jun/16/recovery-trial-for-covid-19-treatments-what-we-know-so-far |accessdate=21 June 2020 |work=[[The Guardian]] |date=16 June 202}}&lt;/ref&gt; Because this is a well tested and widely available treatment this was welcomed by the WHO that is in the process of updating treatment guidelines to include dexamethasone or other steroids.&lt;ref&gt;{{cite web |title=WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients |url=https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients |website=[[World Health Organization]] (WHO) |accessdate=21 June 2020 |date=16 June 2020}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|title=Q&amp;A: Dexamethasone and COVID-19|url=https://www.who.int/news-room/q-a-detail/q-a-dexamethasone-and-covid-19|access-date=12 July 2020|website=[[World Health Organization]] (WHO)}}&lt;/ref&gt; Based on those preliminary results, dexamethasone treatment has been recommended by the [[National Institutes of Health]] for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen.&lt;ref&gt;{{Cite web|date=|title=Corticosteroids|url=https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/corticosteroids/|access-date=12 July 2020|website=COVID-19 Treatment Guidelines|publisher=National Institutes of Health}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>[[Tocilizumab]] has been included in treatment guidelines by China's [[National Health Commission]] after a small study was completed.&lt;ref name="tocil-1"&gt;{{cite news|last1=Liu|first1=Roxanne|last2=Miller|first2=Josh|name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc|url=https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF|title=China approves use of Roche drug in battle against coronavirus complications|date=3 March 2020|work=[[Reuters]]|access-date=14 March 2020|archive-url=https://web.archive.org/web/20200312204625/https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF|archive-date=12 March 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="tocil-2"&gt;{{cite journal|vauthors=Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H|date=19 May 2020|title=Effective treatment of severe COVID-19 patients with tocilizumab|journal=Proc Natl Acad Sci U S A|volume=117|issue=20|pages=10970–10975|doi=10.1073/pnas.2005615117|pmc=7245089|pmid=32350134}}&lt;/ref&gt; It is undergoing a [[Phase IIb|Phase{{nbsp}}II]] non-randomised trial at the national level in Italy after showing positive results in people with severe disease.&lt;ref&gt;{{cite web |last1=Ovadia |first1=Daniela |last2=Agenzia |first2=Zoe |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=COVID-19&amp;nbsp;– Italy launches an independent trial on tocilizumab |url=https://www.univadis.co.uk/viewarticle/covid-19-italy-launches-an-independent-trial-on-tocilizumab-715741 |website=Univadis from Medscape |publisher=Aptus Health |access-date=22 April 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite web |title=Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04317092 |website=www.clinicaltrials.gov |access-date=22 April 2020}}&lt;/ref&gt; Combined with a [[Ferritin|serum ferritin blood test]] to identify a [[cytokine storm]] (also called cytokine storm syndrome, not to be confused with [[cytokine release syndrome]]), it is meant to counter such developments, which are thought to be the cause of death in some affected people.&lt;ref name="tocil-5"&gt;{{cite web|url=https://www.vox.com/2020/3/12/21176783/coronavirus-covid-19-deaths-china-treatment-cytokine-storm-syndrome|title=How doctors can potentially significantly reduce the number of deaths from Covid-19|work=[[Vox (website)|Vox]]|access-date=14 March 2020|date=12 March 2020|archive-url=https://web.archive.org/web/20200319155218/https://www.vox.com/2020/3/12/21176783/coronavirus-covid-19-deaths-china-treatment-cytokine-storm-syndrome|archive-date=19 March 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="tocil-6"&gt;{{cite journal |vauthors=Ruan Q, Yang K, Wang W, Jiang L, Song J |title=Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China |journal=Intensive Care Medicine |date=March 2020 |volume=46 |issue=5 |pages=846–848 |pmid=32125452 |pmc=7080116 |doi=10.1007/s00134-020-05991-x}}&lt;/ref&gt;&lt;ref name="tocil-8"&gt;{{cite journal |vauthors=Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ |title=COVID-19: consider cytokine storm syndromes and immunosuppression |journal=Lancet |volume=395 |issue=10229 |pages=1033–1034 |date=March 2020 |pmid=32192578 |doi=10.1016/S0140-6736(20)30628-0 |pmc=7270045 |doi-access=free}}&lt;/ref&gt; The [[Interleukin 6|interleukin-6]] [[receptor antagonist]] was approved by the [[Food and Drug Administration]] (FDA) to undergo a Phase{{nbsp}}III clinical trial assessing its effectiveness on COVID-19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, [[Chimeric antigen receptor T cell|CAR T cell]] [[Gene therapy|therapy]], in 2017.&lt;ref name="CancerNetworkTocilizumabTrial"&gt;{{cite web |last1=Slater |first1=Hannah |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |title=FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia |url=https://www.cancernetwork.com/news/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia |website=www.cancernetwork.com |date=26 March 2020 |publisher=Cancer Network |access-date=22 April 2020}}&lt;/ref&gt; To date,{{when|date=June 2020}} there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the [[blood-brain barrier]], and exacerbating neurotoxicity while having no effect on the incidence of CRS.&lt;ref&gt;{{cite journal |vauthors=Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Reagan PM, Bot A, Rossi JM, Sherman M, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek JS, Go WY, Miklos DB |display-authors=6 |title=Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL) |journal=Blood |date=2017 |volume=130 |issue=Supplement 1 |pages=1547 |doi=10.1182/blood.V130.Suppl_1.1547.1547 |doi-broken-date=18 October 2020 |url=https://ashpublications.org/blood/article/130/Supplement%201/1547/79746}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984349061
FULLTEXT: <td class="diff-addedline"><div>Transferring purified and concentrated [[Immunoglobulin therapy|antibodies]] produced by the [[immune system]]s of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of [[Passive immunity|passive immunisation]].&lt;ref name="pmid-32167489"&gt;{{cite journal |vauthors=Casadevall A, Pirofski LA |title=The convalescent sera option for containing COVID-19 |journal=The Journal of Clinical Investigation |volume=130 |issue=4 |pages=1545–1548 |date=April 2020 |pmid=32167489 |pmc=7108922 |doi=10.1172/JCI138003}}&lt;/ref&gt;&lt;ref name=":6"&gt;{{cite journal |vauthors=Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N |display-authors=6 |title=Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review |journal=The Cochrane Database of Systematic Reviews |volume=7 |pages=CD013600 |date=July 2020 |pmid=32648959 |doi=10.1002/14651858.CD013600.pub2 |pmc=7389743 |s2cid=220471694}}&lt;/ref&gt; The safety and effectiveness of [[convalescent plasma]] as a treatment option requires further research.&lt;ref name=":6" /&gt; This strategy was tried for SARS with inconclusive results.&lt;ref name="pmid-32167489" /&gt; [[Neutralisation (immunology)|Viral neutralization]] is the anticipated [[mechanism of action]] by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralizing antibodies.&lt;ref name=":1"&gt;{{cite journal |vauthors=Ho M |title=Perspectives on the development of neutralizing antibodies against SARS-CoV-2 |journal=Antibody Therapeutics |volume=3 |issue=2 |pages=109–114 |date=April 2020 |pmid=32566896 |pmc=7291920 |doi=10.1093/abt/tbaa009 |doi-access=free}}&lt;/ref&gt; As of 8 August 2020, eight neutralizing antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies.&lt;ref&gt;{{Cite journal| vauthors = Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M |date=2 July 2020|title=COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 |journal=Antibody Therapeutics |volume=3|issue=3|pages=204–211|doi=10.1093/abt/tbaa020|pmc=7454247}}&lt;/ref&gt; It has been proposed that selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID-19 but also future SARS-related CoV infections.&lt;ref name=":1" /&gt; Other mechanisms, however, such as [[antibody-dependent cellular cytotoxicity]] and/or [[phagocytosis]], may be possible.&lt;ref name="pmid-32167489" /&gt; Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.&lt;ref name="pmid-32167489" /&gt; Production of [[convalescent serum]], which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.&lt;ref name="Pearce-2020-03-13"&gt;{{cite web |last=Pearce |first=Katie |name-list-<ins class="diffchange diffchange-inline">style</ins>=vanc |date=13 March 2020 |title=Antibodies from COVID-19 survivors could be used to treat patients, protect those at risk: Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic |work=The Hub at Johns Hopkins University |url=https://hub.jhu.edu/2020/03/13/covid-19-antibody-sera-arturo-casadevall/ |access-date=14 March 2020 |archive-url=https://web.archive.org/web/20200314185825/https://hub.jhu.edu/2020/03/13/covid-19-antibody-sera-arturo-casadevall/ |archive-date=14 March 2020 |url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984349061
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984349061&oldid=984283217


PRE
Title: Coronavirus disease 2019
ID: 984459932
FULLTEXT: <td class="diff-addedline"><div>* {{cite report | title=COVID-19 infection prevention and control measures for primary care, including general practitioner practices, dental clinics and pharmacy settings: first update | website=[[European Centre for Disease Prevention and Control]] (ECDC) | url=https://www.ecdc.europa.eu/en/publications-data/covid-19-infection-prevention-and-control-primary-care | date=October 2020 }}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=985229760&oldid=984459932
Previous Link: https://en.wikipedia.org//w/index.php?title=Coronavirus_disease_2019&diff=984459932&oldid=984384649


